TerminatedPHASE1, PHASE2NCT04393675
Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
Studying Uremic pruritus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lumosa Therapeutics Co., Ltd.
- Principal Investigator
- June KuoLumosa Therapeutics
- Intervention
- LT5001(drug)
- Enrollment
- 18 target
- Eligibility
- 20-75 years · All sexes
- Timeline
- 2020 – 2022
Study locations (1)
- China Medical University Hospital, Taichung, Taiwan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04393675 on ClinicalTrials.govOther trials for Uremic pruritus
Additional recruiting or active studies for the same condition.